Message on Opioids From HIV Docs to Colleagues Is Clear: Get Training, Prescribe Buprenorphine, Save Lives
Although IDWeek is over, many conference presenters sought to impart one lasting message to their colleagues: Start treating your patients with opioid use disorder and get political about it.
With several new regimens nearing late-stage trials, a new generation of HIV antiretrovirals may soon be entering the marketplace.
A staggering 60% of patients with HIV experience chronic pain compared with only 11% of the general population, according to Robert Bruce, M.D., M.A., M.Sc., who presented the latest research on pain and HIV at IDWeek 2018.
A dial-in hotline program in New York City has helped qualified patients access post-exposure prophylaxis (PEP) at their local pharmacies, raising the possibility that remote screening methods could be an important way to bolster PEP use.
The skin cancer Kaposi Sarcoma (KS) is an HIV-related condition that primarily affects men, but a new cases series presented at IDWeek 2018 in San Francisco highlights the importance of studying women with KS.
Delstrigo, a fixed-dose combination regimen containing the newly approved antiretroviral doravirine (Pifeltro), lamivudine (3TC, Epivir), and tenofovir disoproxil fumarate (Viread), was non-inferior to other triple combination therapies in participan...
A poster presented at the annual IDWeek conference in San Francisco illustrated the lag between the World Health Organization's recommendations and PrEP uptake in an urban setting in Jamaica.
Paul Sax, M.D., provides a rundown of the research that caught his attention at this year's IDWeek conference.
Efavirenz (Sustiva, Stocrin) use was associated with a 60% increased risk of neurological conditions in children, according to data presented at IDWeek 2018 in San Francisco.
A poster presentation at IDWeek in San Francisco revealed that a 21-year-old Latinx man has acquired HIV despite consistently high adherence to pre-exposure prophylaxis (PrEP). But is it of concern?